희소 바이오마커 검체 수집 및 안정화 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Rare Biomarkers Specimen Collection And Stabilization Market Size, Share & Trends Analysis Report By Biomarker (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs)), By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,836,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,322,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,292,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

희소 바이오마커 검체 수집 및 안정화 시장 성장과 동향

그랜드 뷰 리서치(Grand View Research, Inc.)의 최신 보고서에 따르면, 세계 희소 바이오마커 검체 수집 및 안정화 시장 규모는 2025-2030년 연평균 14.4%의 성장률을 기록하며 2030년까지 923억 9,000만 달러에 달할 것으로 예상됩니다. 순환 희귀 바이오마커의 잠재적 사용 확대는 이러한 희소 바이오마커 검체의 효과적이고 신속한 수집 및 안정화를 지원하는 제품 개발에 참여하는 기술 개발자들에게 유리한 기회를 제공하고 있습니다. 또한, 암 검진, 진단, 예후 및 치료 모니터링을 위한 액체 생검의 출현은 희귀 바이오마커 검체 수집 및 안정화 시장에서 경쟁과 역량을 크게 강화하여 수익 성장에 기여하고 있습니다.

순환형 바이오마커는 고부가가치 치료 전달 시스템 및 잠재적인 진단 약품으로서의 잠재력을 가지고 있기 때문에 연구자들은 보다 민감하고 신속하며 유연한 분석 도구를 채택하고 있습니다. 주요 기업들은 연구 가능성을 확대하기 위해 이러한 희귀한 바이오마커 시료의 수집 및 안정화를 위한 새로운 기술과 제품을 개발하고 있습니다. 상당한 장점에도 불구하고, 임상 적용을 극복하기 위한 과제는 여전히 남아 있습니다.

대부분의 분리 방법은 특이성이 높고 민감도가 높지만, 지금까지 임상 샘플에서 제품의 사용 및 효과에 대한 충분한 증거가 없습니다. 이는 이러한 방법들 간의 분석 감도의 차이가 매우 중요한 역할을 하기 때문에 희소 바이오마커 검체의 임상적 활용에 걸림돌이 되고 있습니다. 그러나 이러한 희소 바이오마커 검체의 임상적 유용성에 대한 연구가 증가함에 따라 임상 수행과 관련된 문제를 효과적으로 해결할 수 있을 것으로 기대됩니다.

희소 바이오마커 검체 수집 및 안정화 시장 보고서 하이라이트

• 순환 무세포 DNA(ccfDNA) 부문은 2024년 36.0%로 가장 큰 시장 점유율을 차지했습니다.
• 연구 부문은 2024년 74.1%로 가장 높은 점유율을 차지했습니다. 희귀 바이오마커 부문의 우위는 희귀 바이오마커의 구현에 초점을 맞춘 연구가 증가하고 있기 때문입니다.
• 진단 부문은 2030년까지 CAGR 15.0%로 성장할 것으로 예상됩니다. 순환유주세포 DNA(ccfDNA), 순환종양세포(CTC), 엑소좀과 같은 희귀 바이오마커는 주로 연구 환경에서 사용되어 왔으나, 진단 용도로의 적용이 점점 더 많이 검토되고 있습니다.
• 북미 희소 바이오마커 검체 수집 및 안정화 산업은 2024년 52.1%의 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 희소 바이오마커 검체 수집 및 안정화 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 희소 바이오마커 검체 수집 및 안정화 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 희소 바이오마커 검체 수집 및 안정화 시장 : 바이오마커별, 추정·동향 분석

• 바이오마커 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 바이오마커에 의한 세계의 희소 바이오마커 검체 수집 및 안정화 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 순환 세포 유리 DNA(ccfDNA)
  • 순환종양세포(CTC)
  • 엑소좀/세포외소포
  • 순환 세포 유리 RNA(ccfRNA)/miRNA

제5장 희소 바이오마커 검체 수집 및 안정화 시장 : 최종 용도별, 추정·동향 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 최종 용도에 의한 세계의 희소 바이오마커 검체 수집 및 안정화 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 연구
  • 진단

제6장 희소 바이오마커 검체 수집 및 안정화 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • QIAGEN
  • Charles River Laboratories
  • F. Hoffmann-La Roche Ltd
  • Terumo Medical Corp
  • Thermofischer Scientific Inc
  • Eurofins Scientific
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Siemens Healthcare GmbH

ksm

영문 목차

영문목차

Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends:

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.

Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights:

• The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
• The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
• The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
• North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Biomarker
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Biomarker outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Demand for Precision Medicine
    • 3.2.1.2. Advancements in Liquid Biopsy Technologies
    • 3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs
    • 3.2.2.2. Lack of Standardization
• 3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Estimates & Trend Analysis

• 4.1. Biomarker Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Circulating Cell Free DNA (ccfDNA)
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Circulating Tumor Cells (CTCs)
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.3. Exosomes/Extracellular Vesicles
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.2. By Product
      • 4.4.3.2.1. Isolation Kits & Reagents
        • 4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.2. Blood Collection Tubes
        • 4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.3. Systems
        • 4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.3. By Specimen Type
      • 4.4.3.3.1. Serum/Plasma
        • 4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.3.2. Others
        • 4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.4. By Nucleic Acid & Other Biomolecules
      • 4.4.3.4.1. RNA
        • 4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.2. DNA
        • 4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.3. Others
        • 4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.5. By Application
      • 4.4.3.5.1. NIPT
        • 4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.2. Oncology
      • 4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.1. Research
          • 4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.2. Diagnostics
          • 4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.3.5.3.2.2. Screening
    • 4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.3.2.3. Treatment Monitoring
    • 4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.4. Transcriptomics
        • 4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.5. Pharmacogenomics
        • 4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.6. Transplant Rejection
        • 4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.7. Population Screening
        • 4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.8. Cardiovascular Diseases
        • 4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.9. Other Applications
        • 4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.2. By Product
      • 4.4.4.2.1. Isolation Kits & Reagents
        • 4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.2.2. Blood Collection Tubes
        • 4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.3. By Application
      • 4.4.4.3.1. NIPT
        • 4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.2. Oncology
        • 4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.2. Research
          • 4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.3. Diagnostics
          • 4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.3. Transcriptomics
        • 4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.4. Pharmacogenomics
        • 4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.5. Transplant Rejection
        • 4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.6. Population Screening
        • 4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.7. Cardiovascular Diseases
        • 4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.8. Other Applications
        • 4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 5. Rare Biomarkers Specimen Collection and Stabilization Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Research
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.1.2. Research Labs/CROs
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Academic Institutes
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Diagnostics
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laboratories
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Hospitals
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.4. Prenatal clinics
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare Biomarkers Specimen Collection and Stabilization Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.1.5. )
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
  • 7.3.2. QIAGEN
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Charles River Laboratories
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. F. Hoffmann-La Roche Ltd
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Terumo Medical Corp
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Thermofischer Scientific Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Eurofins Scientific
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. PerkinElmer Inc
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Bio-Rad Laboratories, Inc
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Agilent Technologies, Inc
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Merck KGaA
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Siemens Healthcare GmbH
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives

관련자료